Domov › Rakovina žalúdka › Pennsylvania › Pittsburgh
Klinické štúdie Rakovina žalúdka v meste Pittsburgh, PA
14 štúdií pre Rakovina žalúdka hľadá účastníkov v zariadeniach v meste Pittsburgh a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
Distance-Based Exercise to Preserve Function and Prevent Disability
Prebieha nábor
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Prebieha náborFáza 2/3
- UPMC Hillman Cancer Center, Pittsburgh
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
Prebieha náborFáza 2
- Research Site, Pittsburgh
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Prebieha náborFáza 1
- University of Pittsburgh Medical Center, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Prebieha náborFáza 1/2
- Allegheny Health Network, Pittsburgh
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
Prebieha náborFáza 1
- UPMC Hillman Cancer Center, Pittsburgh
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Prebieha náborFáza 3
- Research Site, Pittsburgh
- Research Site, Pittsburgh
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Prebieha náborFáza 1/2
- University of Pittsburgh Medical Center, Pittsburgh
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Prebieha náborFáza 1/2
- Research Site, Pittsburgh
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Prebieha náborFáza 1
- University of Pittsburg Medical Center _UPMC Hillman Cancer Center, Pittsburgh
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Prebieha náborFáza 1/2
- University of Pittsburgh Medical Center, Pittsburgh
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Prebieha náborFáza 3
- UPMC Hillman Cancer Center, Pittsburgh
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
Prebieha náborFáza 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
Prebieha náborFáza 1
- AHN West Penn Hospital, Pittsburgh
Štúdie Rakovina žalúdka v iných mestách
- Houston, TX42 štúdií
- Boston, MA32 štúdií
- New York City, NY31 štúdií
- Nashville, TN28 štúdií
- Baldwin Park, CA22 štúdií
- Los Angeles, CA22 štúdií
- Arlington, VA20 štúdií
- Dallas, TX19 štúdií
- San Antonio, TX19 štúdií
- St. Louis, MO18 štúdií
- Grand Rapids, MI18 štúdií
- Washington, DC16 štúdií
Iné štúdie v Pittsburgh
- Nemalobunkový karcinóm pľúc48 štúdií
- Rakovina (všetky typy)41 štúdií
- Rakovina prsníka39 štúdií
- Kolorektálny karcinóm32 štúdií
- Metastatická rakovina31 štúdií
- Melanóm31 štúdií
- Rakovina vaječníkov30 štúdií
- Rakovina endometria23 štúdií
- Rakovina prostaty23 štúdií
- Rakovina pľúc23 štúdií
- Skvamóznocelulárny karcinóm hlavy a krku22 štúdií
- Cievna mozgová príhoda22 štúdií
Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.